COMMUNIQUÉS West-GlobeNewswire

-
Lisata Therapeutics to Present at BIO CEO & Investor Conference
20/02/2024 -
Aligos Therapeutics to Host KOL Event to Discuss Phase 2a HERALD Study of ALG-055009 in MASH on March 7, 2024
20/02/2024 -
Tonix Pharmaceuticals to Participate in the 2024 BIO CEO & Investor Conference
20/02/2024 -
Monopar Receives Clearance to Proceed with First-in-Human Phase 1 Trial of Novel Radiopharmaceutical MNPR-101-Zr in Advanced Cancers
20/02/2024 -
NMDP Announces Enrollment of First Patient in OPTIMIZE Clinical Trial
20/02/2024 -
Ayala Pharmaceuticals Announces Completion of Enrollment in Phase 3 RINGSIDE Study Evaluating AL102 in Desmoid Tumors
20/02/2024 -
Clinical Research Data Sharing Alliance (CRDSA) Hosts Virtual Summit
20/02/2024 -
ProPhase Labs Announces Significant Progress in BE-Smart Esophageal Cancer Test Development USPTO grants additional broad patents for BE-SMART
20/02/2024 -
TransCode Therapeutics Reports Publication of United States Patent Application Covering TransCode’s RIG-I Agonist Immunotherapeutic
20/02/2024 -
PepGen Receives U.S. FDA Fast Track Designation for PGN-EDODM1 for the Treatment of Myotonic Dystrophy Type 1
20/02/2024 -
Mestag Therapeutics Enlists Leading Cancer Biology and Immunology Advisors to Support Clinical Development of its Lead Oncology Program
20/02/2024 -
IntelGenx Launches Preferred Share Regulation A Offering
20/02/2024 -
Gracell Biotechnologies Announces Shareholders’ Approval of Merger Agreement
20/02/2024 -
Kura Oncology to Report Fourth Quarter and Full Year 2023 Financial Results
20/02/2024 -
Evaxion Announces Successful Completion of the Initial Phases of Ongoing Vaccine Collaboration with MSD
20/02/2024 -
Matinas BioPharma Successfully Reaches Agreement with FDA for a Single Phase 3 Registration Trial to Support an NDA for MAT2203 for the Treatment of Invasive Aspergillosis
20/02/2024 -
Venus Concept to Release Fourth Quarter and Fiscal Year 2023 Financial Results on April 1, 2024
20/02/2024 -
Theratechnologies Announces Publication in Frontiers in Immunology that Deepens Understanding of Sudocetaxel Zendusortide (TH1902) Molecular Mechanism of Action
20/02/2024 -
Theratechnologies annonce la publication d’un article dans Frontiers in Immunology qui approfondit la compréhension du mécanisme d’action moléculaire du sudocétaxel zendusortide (TH1902)
20/02/2024
Pages